{"id":265111,"date":"2026-06-03T15:39:15","date_gmt":"2026-06-03T15:39:15","guid":{"rendered":"https:\/\/www.europesays.com\/se\/265111\/"},"modified":"2026-06-03T15:39:15","modified_gmt":"2026-06-03T15:39:15","slug":"dicot-pharma-frias-av-nasdaqs-disciplinnamnd","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/265111\/","title":{"rendered":"Dicot Pharma frias av Nasdaqs disciplinn\u00e4mnd"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nasdaqs disciplinn\u00e4mnd har kommit fram till att forskningsbolaget Dicot Pharma inte har brutit mot Nasdaq Stockholms regelverk och d\u00e4rf\u00f6r inte ska tilldelas n\u00e5gon sanktion. Det framg\u00e5r av ett pressmeddelande.\n <\/p>\n<p>\u00c4rendet r\u00f6rde bolagets kommunikation kring resultaten fr\u00e5n en fas 2a-studie.\n <\/p>\n<p>Disciplinn\u00e4mnden bed\u00f6mer att informationen hade kunnat presenteras tydligare, men anser samtidigt att bolaget inte br\u00f6t mot marknadsmissbruksf\u00f6rordningens krav p\u00e5 offentligg\u00f6rande av insiderinformation eller skyldigheten att l\u00e4mna information p\u00e5 ett s\u00e4tt som m\u00f6jligg\u00f6r en fullst\u00e4ndig, korrekt och snabb bed\u00f6mning av uppgifterna.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Reno Santic<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<br \/>\n <br class=\"col-start-2\"\/><br \/>\n <a class=\"twitter-timeline\" data-width=\"1200\" data-height=\"1000\" data-dnt=\"true\" href=\"https:\/\/s.com\/Finwire\" rel=\"nofollow\">Posts by Finwire<\/a><script async src=\"https:\/\/platform.x.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\n <br class=\"col-start-2\"\/><br \/>\n newsroom@finwire.se<\/p>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"Nasdaqs disciplinn\u00e4mnd har kommit fram till att forskningsbolaget Dicot Pharma inte har brutit mot Nasdaq Stockholms regelverk och&hellip;\n","protected":false},"author":2,"featured_media":265112,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,5842,70,71,34,31,33,32,30],"class_list":["post-265111","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-dicot-pharma","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116686931033973656","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/265111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=265111"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/265111\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/265112"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=265111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=265111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=265111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}